| November 1 |
Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce
Agreement to Develop and Commercialize Indiplon in Japan |
| November 1 |
AstraZeneca PLC: Third Quarter and Nine Months Results 2007 |
| November 1 |
Crestor ANDA |
| November 1 |
FDA Sends Northeast General Pharmaceutical Factory Warning Letter |
| November 1 |
IMS Health Predicts 5 to 6 Percent Growth for Global Pharmaceutical
Market in 2008, According to Annual Forecast |
| November 1 |
Further Upgrade to 2007 Financial Guidance Based on Strong Revenue
Growth; Vyvanse Demand on Track |
| November 1 |
Dynavax and Merck & Co., Inc. Announce Partnership to Develop
Heplisav, an Investigational Hepatitis B Vaccine Currently in Phase
3 |
| November 1 |
Perrigo Announces that Dexcel's Settlement with AstraZeneca Allows
OTC Omeprazole Launch Following Final FDA Approval |
| November 1 |
All-State Properties, L.P. Announces Termination of Reverse Merger
With Chinese Pharmaceutical Company |
| November 1 |
FDA Says Consumers Continue to Buy Risky Drugs Online |
| November 1 |
Averion International Corp. Acquires Hesperion AG |
| November 1 |
Federal Court Ruling Enjoining PTO Rules is a Sound Decision, Says
BIO |
| November 2 |
ADVENTRX Provides Update on Cofactor Program |
| November 2 |
Dainippon Sumitomo Pharma Signs License Agreement for a Sedative
Hypnotic Agent |
| November 2 |
Medtronic and Kyphon Complete Merger |
| November 2 |
Barr Confirms Patent Challenge of Ritalin LA |
| November 5 |
FDA Requests Marketing Suspension of Trasylol |
| November 5 |
Bayer Temporarily Suspends Global Trasylol Marketing |
| November 5 |
Transition Therapeutics Provides Update on Diabetes Program |
| November 5 |
AstraZeneca Response to November 2, 2007 Ruling In Re:
Pharmaceutical Industry Average Wholesale Price Litigation, MDL No.
1456, U.S. District Court, District of Massachusetts |
| November 5 |
Schering-Plough CEO Calls for Four-Pronged Approach to Improving
Current Health Care Environment |
| November 5 |
FDA Requests Marketing Suspension of Trasylol |
| November 5 |
Bayer Temporarily Suspends Global Trasylol Marketing |
| November 5 |
Manipal AcuNova and ECRON Merge to Form ECRON AcuNova |
| November 5 |
Targacept to Receive $2 Million from AstraZeneca for Option to Lead
Product Candidate in Alpha7 NNR Program |
| November 5 |
Novacea Halts ASCENT-2 Trial in Advanced Prostate Cancer |
| November 5 |
GlaxoSmithKline Initiates Trials of Promacta/revolade (eltrombopag)
to Investigate the Potential to Aid Hepatitis C Patients in
Achieving Sustained Virological Response |
| November 5 |
Takeda's Investigational Compound TAK-442 for Treatment of
Venous/Arterial Thromboembolism Enters into Phase 2 Clinical Stage
in the U.S. and Europe |
| November 5 |
Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues
Stinging Rebuke in Average Wholesale Price Case |
| November 5 |
FDA Selects Members for Risk Communication Advisory Committee |
| November 5 |
CELSION Provides Update on Status of Special Protocol Assessment
(SPA) Submission |
| November 6 |
GTx, Inc. and Merck & Co., Inc. Enter Global Strategic
Collaboration for the Development of SARMs, a Novel Investigational
Class of Drugs to Treat Muscle Loss and other Musculoskeletal
Conditions |
| November 6 |
Schering-Plough Reports U.S. District Court for District of
Massachusetts Finds No Liability for Subsidiary in AWP Case |
| November 6 |
New Galvus Clinical Data Reinforces Efficacy Profile; Safety Update
Provided to Regulatory Agencies |
| November 6 |
Bayer Expects a Record Year in 2007 |
| November 6 |
EPIX Pharmaceuticals Achieves Milestone For Second Discovery
Program in Collaboration with GlaxoSmithKline |
| November 6 |
AstraZeneca Announces Nexium(esomeprazole magnesium) Savings
Program for Purple Plus Members |
| November 6 |
Allergan Reports Third Quarter Operating Results |
| November 6 |
Remicade Becomes First Anti-TNF Biologic Therapy to Treat One
Million Patients Worldwide |
| November 6 |
VWR International, LLC Acquires Netherlands-Based Omnilabo
International B.V. |
| November 6 |
BIOBASE Enters into a Custom Curation Service Agreement with
Procter & Gamble |
| November 6 |
Court Throws Out Claim in Johnson & Johnson Lawsuit Against the
American Red Cross |
| November 6 |
Avandia Withdrawals Increase and Accelerate after Reports of
Potential Cardiovascular Risk, According to TNS Healthcare |
| November 7 |
Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34)
Nasal Spray from Procter & Gamble |
| November 7 |
Watson Files FDA Application for Generic YAZ |
| November 7 |
Alcon Gains All Regulatory Clearances for Acquisition of WaveLight
AG |
| November 7 |
Agilent Technologies Signs Agreement to Acquire Velocity11, a
Leader in Life Science Lab Automation and Robotics |
| November 7 |
Tweens Double Use of Diabetes Drugs |
| November 7 |
Omnicare Comments on Analyst and Press Reports |
| November 7 |
Entelos Finalizes Initial Consideration for Iconix Biosciences,
Inc. Acquisition |
| November 8 |
Prometheus to Acquire Lotronex From GlaxoSmithKline |
| November 8 |
ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial
Results |
| November 8 |
Abraxis BioScience Announces the Closing Date for the Separation of
Its Proprietary Business from Its Hospital-Based Business |
| November 8 |
Astellas and Boehringer Ingelheim Reach Settlement Agreement with
Ranbaxy on Flomax Patent Case |
| November 8 |
Ranbaxy and Astellas/Boehringer Ingelheim Enter Into an Agreement
to Resolve Tamsulosin U.S. Patent Litigation |
| November 8 |
Amgen to Provide New Evidence as Part of a Formal Reconsideration
of CMS' National Coverage Determination on ESAs |
| November 8 |
FDA Sends Scios Letter for Natrecor |
| November 8 |
Amgen Announces Updates to the U.S. Prescribing Information for
ESAs |
| November 8 |
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US
Licensing Agreement to Develop and Commercialize Amigal, Plicera
and At2220 |
| November 8 |
Dyax Corp. Announces Extension of Antibody Library Collaboration
with ImClone Systems |
| November 8 |
Ortho Biotech to Submit Official Request for Reconsideration to CMS
Regarding ESA Coverage Policy |
| November 9 |
Merck Agreement to Resolve U.S. Vioxx Product Liability Lawsuits |
| November 9 |
The Lanier Law Firm Announces $4.85 Billion National Vioxx
Settlement with Merck & Co. Inc. |
| November 9 |
Results of a Survey of Parents' Perceptions of the Duration of
Their Child's ADHD Medication Reported at Medical Meeting |
| November 12 |
AtheroGenics Modifies ANDES Clinical Trial Discontinuing Highest
Dose of AGI-1067 |
| November 12 |
MedZilla.com Releases its October Employment Outlook Numbers for
Biotechnology, Pharmaceuticals, Healthcare & Science |
| November 12 |
PAION is Seeking a New US-Partner for Desmoteplase |
| November 13 |
Nanogen to Close Array Business - Will Focus on Two High Growth
Product Lines |
| November 13 |
Cegedim Strategic Data (CSD) Acquires 3ES |
| November 13 |
Pfizer and Nektar Reach Agreement on Exubera |
| November 13 |
Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine
to Market |
| November 13 |
Orion Sues Sun Pharmaceuticals in the U.S. to Enforce a Patent for
Stalevo |
| November 13 |
Entelos Announces Expanded Research with Pfizer |
| November 14 |
Merck Serono Exercises Option to Rigel's R763/AS703569 and Aurora
Kinase Inhibitors in the Japanese Territory |
| November 14 |
Roche Confirms Commencement of Due Diligence with Ventana |
| November 14 |
Nastech Pharmaceutical Company Initiates Plan for Corporate
Restructuring and Will Concentrate on Phase 2 Clinical Programs |
| November 14 |
STEP Study Volunteers to be Informed Whether They Received Vaccine
or Placebo |
| November 14 |
Fluorotechnics Expands Global Capability via Acquisition of ETC
Elektrophorese-Technik |
| November 14 |
NeoStem, Inc. Acquires Stem Cell Technologies, Inc. from UTEK
Corporation |
| November 14 |
Early Communication About an Ongoing Safety Review Cefepime
(marketed as Maxipime) |
| November 14 |
Number of Cases of Most Vaccine-Preventable Diseases in U.S. at
All-Time Low |
| November 14 |
GSK Revises US Labeling for Avandia |
| November 14 |
FDA Issues an Information for Healthcare Professionals Sheet for
Viagra, Levitra, and Cialis |
| November 15 |
GPC Biotech Announces Corporate Restructuring |
| November 15 |
Dragon Sells EPO Business; Focus on Antibiotic Core Business |
| November 15 |
Johnson & Johnson Announces Changes to Accelerate Growth |
| November 15 |
PerkinElmer Completes Acquisition of ViaCell |
| November 15 |
JDRF and Lilly Partner to Fund Research to Identify Beta Cell
Biomarkers |
| November 15 |
NCCN Receives Major Grant for Anti-Cancer Drug Study |
| November 15 |
FDA Announces Steps to Improve Advisory Committee Processes |
| November 15 |
Getting Ready Corporation and Winston Laboratories, Inc. Announce
Merger Agreement |
| November 15 |
Sanofi-aventis Announces New Research Center in Oro Valley |
| November 16 |
Cambridge Major Laboratories Adds ChemShop B.V. |
| November 16 |
UCB to Appeal European Negative Opinion on Cimzia for the Treatment
of Patients with Crohn's Disease |
| November 16 |
Pfizer to Acquire Coley Pharmaceutical Group |
| November 16 |
Argos Therapeutics and Therakos, Inc. Enter Exclusive Agreement for
Regulatory T Cell Technology |
| November 16 |
Schering-Plough Receives Clearance From U.S. Federal Trade
Commission for Planned Acquisition of Organon Biosciences N.V. |
| November 16 |
Floor Statement of U.S. Senator Chuck Grassley of Iowa Ranking
Member of the Committee on Finance Intimidation of Scientists |
| November 19 |
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock |
| November 19 |
Genelabs Technologies Regains Exclusive Rights to Prestara in Japan
From Mitsubishi Tanabe Pharma Corporation |
| November 19 |
Cognizant Completes the Acquisition of marketRx |
| November 19 |
FDA Announces Board Members of Reagan-Udall Foundation |
| November 19 |
Nycomed Significantly Increases Profitability |
| November 19 |
Boston Scientific Announces Amended Agreement to Settle Product
Lawsuits |
| November 19 |
Sciele Signs Exclusive Agreement with Novo Nordisk to Market
Prandin and PrandiMet |
| November 19 |
Schering-Plough Completes Acquisition of Organon BioSciences |
| November 19 |
United Kingdom and Germany Suspend Marketing and Sale of Prexige
Pending Outcome of European Regulatory Review |
| November 19 |
EPO Rules AstraZeneca MUPS Patent Valid |
| November 20 |
Biogen Idec and Neurimmune Therapeutics Announce Alliance to
Develop Treatments for Alzheimer's Disease |
| November 21 |
92 Medicines and Vaccines now in Development for HIV/AIDS |
| November 21 |
Anika Therapeutics and Galderma Agree to Terminate License,
Development and Supply Agreements |
| November 21 |
FDA-MedWatch- Chantix (Varenicline)-FDA Reviewing Post Marketing
Cases Describing Suicidal Ideation And Occasional Suicidal Behavior |
| November 21 |
FDA Issues Early Communication for Chantix |
| November 21 |
GSK to Acquire Reliant Pharmaceuticals |
| November 21 |
GlaxoSmithKline to Acquire Reliant Pharmaceuticals |
| November 21 |
Alkermes Announces Proceeds of Up to $174 Million from Sale of
Stake in Reliant Pharmaceuticals and Plans to Repurchase Shares of
Its Common Stock |
| November 26 |
Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine
Development Status |
| November 26 |
InterMune Buys Out License Agreement for Pirfenidone |
| November 26 |
Simcere Acquires Nanjing Tung Chit |
| November 26 |
Intercell/Novartis Alliance – Next EUR 80 Million Payment
Received |
| November 26 |
Maxygen Updates Status of MAXY-alpha Program |
| November 26 |
OncoMethylome Sciences to Collaborate with GlaxoSmithKline
Biologicals for Personalized Cancer Treatment |
| November 26 |
Beijing Med-Pharm Announces Exclusive Agreement to Market Enablex
in China |
| November 26 |
Targeted Genetics Announces That FDA Has Removed Hold on Phase I/II
Clinical Trial of tgAAC94 for Inflammatory Arthritis |
| November 26 |
Health Media Announces Acquisition of the Embryon Group Companies |
| November 27 |
Sepracor Inc. Announces Completion of SEC Investigation |
| November 27 |
Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two
Additional Lead Compounds |
| November 27 |
Taconic Acquires 80% Stake in Artemis |
| November 27 |
FDA Sends Warning Letter to GlaxoSmithKline Over 'Dear Healthcare
Practitioner' Letters |
| November 27 |
ImmunoCellular Therapeutics Agrees to Acquire Molecular Antibody
Technology |
| November 27 |
Drugs May Not Delay Onset of Dementia |
| November 27 |
U.S. Department of Health and Human Services Completes Funding of
2006 Contract Award to CSC's DVC and Baxter |
| November 27 |
Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical
Biomarker Research Into Clinical Study Design |
| November 27 |
Maxygen Announces Plans to Consolidate Operations in the U.S. |
| November 27 |
Myfortic (mycophenolic acid) Delayed- Release Tablets - Use of Drug
During Pregnancy Associated with Increased Risks of Pregnancy Loss
and Congenital Malformations |
| November 28 |
eResearchTechnology (eRT) Agrees to Acquire the Centralized ECG
Business of Covance |
| November 28 |
Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune
(nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in
Treatment-Naive HIV Patients |
| November 28 |
QLT Board Authorizes Exploration of Strategic Alternatives to
Enhance Near- to Mid-Term Shareholder Value |
| November 29 |
Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for
Achievement of Liver X Receptor Agonist Development Milestone |
| November 29 |
OPKO Health Completes Acquisition of Ophthalmic Technologies, Inc. |
| November 29 |
ChemGenex Announces Shareholder Approval to Demerge Verva
Pharmaceuticals |
| November 29 |
New LJS Study Finds Broad Consumer Acceptance of Behind-The-Counter
Drugs |
| November 29 |
Regeneron Initiates Major Global Collaboration with Sanofi-aventis
to Develop and Commercialize Fully-Human Therapeutic Antibodies |
| November 29 |
Bavarian Nordic A/S Reports Positive Data from First EUA Enabling
Study with Imvamune Smallpox Vaccine |
| November 29 |
Diabetes Patients Withdrawn from Avandia Are Most Likely Switched
to the New First-in-class Agents, Januvia or Byetta, According to
Tns Healthcare |
| November 29 |
MGI PHARMA Issues Statement |
| November 29 |
GSK Statement on US Food and Drug Administration Pediatric Advisory
Committee Recommendations Regarding Salmeterol |
| November 29 |
Kyowa Hakko Interim Operating Income up 25.2% |
| November 29 |
Axcan Pharma Inc. to be Acquired by TPG Capital and Affiliates for
US$1.3 Billion or US$23.35 Per Share in Cash |
| November 29 |
Sen. Grassley Says Independent Reviews of FDA Employee Misconduct
Will Better Serve Public |
| November 30 |
Cardinal Health Receives DEA Order to Temporarily Cease
Distribution of Controlled Substances from Auburn, Wash. Facility |
| November 30 |
Boston Scientific Welcomes FDA Panel Recommendation to Approve
Promus / Xience V Everolimus-eluting Coronary Stent System |
| November 30 |
Pfizer Inc Commences Tender Offer for All Outstanding Shares of
Coley Pharmaceutical Group, Inc. |
| November 30 |
Sanofi-Aventis and Astellas to Restructure the Joint Venture
Activities in Japan of Fujisawa Sanofi-Aventis K.K. |
| November 30 |
Speedel Receives First Cost-of-Goods Savings for SPP100 |
